RENATA Renata Limited
Pharmaceuticals & Chemicals
Tk 424.4 as of 2026-11-12 14:00:00
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency Paid a dividend every year (5/5)
- Solvency Low debt: debt/equity 0.49x (below 0.5)
- Valuation Trades near book value (P/NAV 1.25x)
- Ownership Institutions (23.47%) hold more than the public (7.92%)
Concerns
- Consistency EPS rose in only 1 of 4 years (erratic or cyclical)
- Profitability Net profit shrinking 18.61% a year
Notes
- Profitability Average ROE 10.73% (moderate)
- Valuation P/E 12.42 is fair
Risk flags
No flags raised.
Valuation
52-week range
13.2% above the low, 13% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 51.3%
- Institution 23.5%
- Foreign 17.3%
- Public 7.9%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 51.94 | 263.85 | 506 | 145 | 10 |
| 2022 | 47.68 | 274.39 | 511 | 140 | 7 |
| 2023 | 20.4 | 266.87 | 234 | 62.5 | 0 |
| 2024 | 31.53 | 295.56 | 362 | 92 | 0 |
| 2025 | 19.36 | 305.49 | 222 | 55 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 38.8%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.